Indian Journal of Ophthalmology (Jan 2012)
Managing bevacizumab-induced intraocular inflammation
- Subijay Sinha,
- Nagender Vashisht,
- Pradeep Venkatesh,
- Sat Pal Garg
Affiliations
- Subijay Sinha
- Nagender Vashisht
- Pradeep Venkatesh
- Sat Pal Garg
- DOI
- https://doi.org/10.4103/0301-4738.98712
- Journal volume & issue
-
Vol. 60,
no. 4
pp. 311 – 313
Abstract
The outcome of four cases of sterile endophthalmitis that developed after intravitreal injections of bevacizumab has been reported here. All four eyes received 1.25 mg/0.05 ml intravitreal bevacizumab from 0.2-ml aliquots for different etiologies. The inflammation predominantly involved the anterior chamber with mild vitreous reaction. All patients were culture negative and regained preinjection visual acuity and were culture negative following intravitreal antibiotic administration. This report highlights that intravitreal bevacizumab can cause sterile endophthalmitis and this has to be kept in mind, and clinical judgment should be used to differentiate it from infective endophthalmitis.
Keywords
- Apoptosis
- glaucoma
- intraocular pressure
- retinal ganglion cells
- retinal ischemia
- tumor necrosis factor-alpha
- Branch retinal vein occlusion
- laser
- Lucentis
- macular edema
- Microbial etiology
- mucopurulent keratitis
- suppurative keratitis
- Intraoperative application of mitomycin C
- mitomycin C
- postoperative complications
- preoperative subconjunctival injection
- recurrence rate
- recurrent pterygium
- Cataract
- inflammation
- mydriasis
- prevention and control
- surgery
- Cross-cylinder technique
- photoastigmatic refractive keratectomy
- refractive surgery
- ′BARC I-125 Ocu-Prosta seeds′
- choroidal melanoma
- plaque brachytherapy
- retinoblastoma
- vasoproliferative tumors
- Asian Indian
- Amaurosis
- amaurosis hemianopia
- capsulolenticular cataract
- conjunctiva
- lenticular cataract
- leukoma
- eye lid
- ophthalmia chronica
- ophthalmic purulentis
- Interpretation
- magnetic resonance imaging
- orbit
- ophthalmology
- Antivascular endothelial growth factor
- intravitreal bevacizumab
- ocular inflammation